What is LQDA (LQDA) stock price today?

LQDA (LQDA) is currently trading at $66.91, down 1.85% today.

What is LQDA P/E ratio?

LQDA's P/E ratio is 43.45. This is above the market average, reflecting high growth expectations.

What is LQDA return on equity (ROE)?

LQDA's return on equity (ROE) is 149.64%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is LQDA's market cap?

LQDA has a market capitalization of $5.95B.

NASDAQ · Biotechnology

LQDA (LQDA) Stock

$66.91 -1.85% NASDAQ: LQDA Healthcare

Valuation

Metric	Value
Price	$66.91
Market Cap	$5.95B
P/E Ratio	43.45
P/B Ratio	31.06
P/S Ratio	13.44
EPS (TTM)	$-0.80
52-Week High	$93.61
52-Week Low	$21.15
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	149.64%
ROA	26.56%
ROCE	50.68%
Gross Margin	98.72%
Operating Margin	15.81%
Net Margin	30.74%
Debt/Equity	0.66
Current Ratio	2.01

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$13.0M	$16.0M	$17.0M	$14.0M	$158.0M
Operating Profit	$-34.0M	$-39.0M	$-73.0M	$-121.0M	$-51.0M
Net Profit	$-35.0M	$-41.0M	$-79.0M	$-130.0M	$-69.0M
EPS	$-0.70	$-0.67	$-1.21	$-1.66	$-0.80
Op Margin	-262.9%	-243.3%	-419.6%	-866.6%	-32.5%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$94.0M	$129.0M	$118.0M	$230.0M	$328.0M
Total Liabilities	$28.0M	$39.0M	$71.0M	$153.0M	$283.0M
Cash	$57.0M	$93.0M	$84.0M	$176.0M	$191.0M
Borrowings	$16.0M	$24.0M	$50.0M	$122.0M	$198.0M

Latest News

Here's Why You Should Add INKT Stock to Your Portfolio Now Zacks · Jul 16, 2026 Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance Zacks · Jul 16, 2026 Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal Zacks · Jul 15, 2026 Liquidia Insider Sold Shares Worth $2,520,683, According to a Recent SEC Filing MT Newswires · Jul 15, 2026 Liquidia Insider Sold Shares Worth $1,460,965, According to a Recent SEC Filing MT Newswires · Jul 15, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-34.0M	$-29.0M	$-42.0M	$-93.0M	$-36.0M
Investing Cash Flow	$0	$-1.0M	$-13.0M	$-13.0M	$-11.0M
Financing Cash Flow	$5.0M	$2.0M	$0	$4.0M	$1.0M
Net Cash Flow	$-8.0M	$36.0M	$-10.0M	$93.0M	$14.0M
Free Cash Flow	$-34.0M	$-29.0M	$-43.0M	$-98.0M	$-40.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.02
EV / EBITDA	33.22
FCF Yield	1.00%
Quick Ratio	2.12
Interest Coverage	6.33
Return 1Y	146.50%
Return 3Y	854.72%
Return 5Y	2498.89%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AGIO	$34.21	+1.57%	-3.56	$2.04B	0.00%
COGT	$34.68	-0.91%	-34.70	$5.93B	0.00%
DNLI	$23.27	-2.08%	-6.20	$3.69B	0.00%
ETNB89bio, Inc.	$14.84	+0.00%	-12.82	$2.20B	0.00%
GLPGGalapagos N.V.	$27.98	+1.71%	3.57	$1.84B	0.00%

About LQDA

LQDA is led by CEO Roger A. Jeffs, employs 216 people, headquartered in Morrisville, US, publicly traded since 2018.

LQDA stock trades at $66.91 with a market capitalization of $5.95B. The stock is valued at a price-to-earnings (P/E) ratio of 43.45, price-to-book of 31.06, price-to-sales of 13.44. Over the past 52 weeks the stock has ranged between $21.15 and $93.61, and currently trades 28.5% below its 52-week high.

On profitability, LQDA generates a return on equity (ROE) of 149.64% — well above the market average, a sign of a high-quality business, return on capital employed of 50.68%, an operating margin of 15.81%, a net profit margin of 30.74%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides